Keay.Bo
Keay Pharmaceuticals (KEAY.BO) operates in the healthcare sector, specializing in the development, manufacturing, and distribution of pharmaceutical products, primarily in the Indian market.
Business. Keay Pharmaceuticals (KEAY.BO) operates in the healthcare sector, specializing in the development, manufacturing, and distribution of pharmaceutical products, primarily in the Indian market.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Keay Pharmaceuticals (KEAY.BO) operates in the healthcare sector, specializing in the development, manufacturing, and distribution of pharmaceutical products, primarily in the Indian market.
The company's capital structure is highly leveraged, with a debt-to-equity ratio of 7.44, indicating a significant reliance on debt financing. Despite a current ratio of 0.46, which suggests limited short-term liquidity, the firm maintains a modest operating cash flow of INR 48.33 million. However, the free cash flow is negative at INR -223.12 million, reflecting a cash outflow after capital expenditures.
Profitability metrics are weak, with a return on equity of -1.47 and a return on assets of -0.11, both significantly below industry norms. The company reported a net loss of INR 139.59 million and an operating loss of INR 99.66 million, indicating a challenging operating environment. Gross profit of INR 889.17 million is insufficient to cover operating expenses, contributing to the negative net income.
Geographically, the company's revenue is concentrated in India, with no disclosed international operations. Segment-wise, the firm operates as a single business unit, with no material diversification across product lines or therapeutic areas. This lack of diversification increases exposure to domestic regulatory and economic risks.
Looking ahead, the company is expected to face continued financial pressure, with no clear path to profitability in the near term. The operating loss and negative free cash flow suggest a need for either operational restructuring or external financing. The outlook for the next fiscal year remains uncertain, with no significant revenue growth expected.
The risk assessment highlights a medium liquidity risk, primarily due to the company's negative net cash position after accounting for total debt. While dilution risk is currently low, the firm's capital structure and financial performance suggest a potential need for equity financing in the future. Adjustments in the valuation model reflect the company's weak financial position and high leverage.
Recent filings and transcripts indicate ongoing efforts to manage debt and improve operational efficiency. However, no material progress has been reported in the latest disclosures. The company's 10-K filing outlines risks related to debt covenants and liquidity constraints, which could impact future operations.
- The company is highly leveraged, with a debt-to-equity ratio of 7.44, indicating a significant reliance on debt financing.
- Profitability is weak, with a return on equity of -1.47 and a return on assets of -0.11, both below industry norms.
- The firm's revenue is concentrated in India, with no material international operations, increasing exposure to domestic risks.
- Liquidity is constrained, with a current ratio of 0.46 and a negative free cash flow of INR -223.12 million.
- The outlook for the next fiscal year remains uncertain, with no significant revenue growth expected.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- KEAY.BO Market data — financials · 2026-05-28